Skip to main
BCRX
BCRX logo

BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharmaceuticals (BCRX) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 52%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

BioCryst Pharmaceuticals Inc. has experienced a notable increase in sales, reaching 13.9% of global revenues in the fourth quarter of 2024, up from 11.4% in the previous quarter, signaling robust growth momentum. The company's flagship product, Orladeyo, is gaining traction among physicians, with 59% now extremely likely to prescribe it, reflecting a 26% increase compared to early 2023, which bodes well for future revenue. Furthermore, with projected Orladeyo revenue guidance for 2025 raised to $535M-$550M, alongside a broader total revenue forecast increase, BioCryst is well-positioned to reach its ambitious target of $1B in peak global sales by 2029, underpinned by its product's efficacy and improved reimbursement conditions.

Bears say

BioCryst Pharmaceuticals Inc. is facing significant challenges that contribute to a negative financial outlook, including a forecast of flat to lower sales for Orladeyo in 1Q24, primarily due to the substantial reauthorization process affecting approximately 50% of patients. The company has consistently reported losses since its inception, with a notable net loss of $26.8 million for 4Q24, raising concerns about its pathway to profitability, which is still likely several years away. Additionally, operational expenses exceeded market expectations in 4Q24, driven by higher-than-expected selling, general, and administrative costs, further complicating the company's financial stability.

BioCryst Pharmaceuticals (BCRX) has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 52% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCryst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCryst Pharmaceuticals (BCRX) Forecast

Analysts have given BioCryst Pharmaceuticals (BCRX) a Buy based on their latest research and market trends.

According to 21 analysts, BioCryst Pharmaceuticals (BCRX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCryst Pharmaceuticals (BCRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.